Dengue amidst COVID-19 : challenges & control measures for the double burden
Dengue, an arbovirus, is a public health treat in the tropics and sub-tropical climates worldwide. The disease incidence has grown dramatically worldwide, with an estimated 390 million dengue virus infection per year. Dengue has distinct epidemiological patterns which are associated with the four virus serotypes. All four serotypes can co-circulate within a region, in which a number of regions are hyperendemic for all 4 serotypes. Currently, there are no specific treatment or vaccine for the disease. Dengue prevention depends on vector control measures and early interventions. The COVID-19 pandemic has placed immense pressure on health care and management systems worldwide. During the COVID-19 pandemic, the situation was aggravated by the simultaneous dengue outbreaks, that has led to a double burden which has further impacted the healthcare sector, particularly in resource limited settings. This review article will focus on dengue epidemics during the COVID-19 pandemic and discuss on recent findings on immunological cascades between dengue and COVID-19 and, the impact on vaccine development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Uirusu - 71(2021), 1 vom: 06., Seite 1-10 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Moi, Meng Ling [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 10.05.2022 Date Revised 10.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2222/jsv.71.1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340554568 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340554568 | ||
| 003 | DE-627 | ||
| 005 | 20231226005606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2021 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.2222/jsv.71.1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340554568 | ||
| 035 | |a (NLM)35526989 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Moi, Meng Ling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dengue amidst COVID-19 |b challenges & control measures for the double burden |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2022 | ||
| 500 | |a Date Revised 10.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Dengue, an arbovirus, is a public health treat in the tropics and sub-tropical climates worldwide. The disease incidence has grown dramatically worldwide, with an estimated 390 million dengue virus infection per year. Dengue has distinct epidemiological patterns which are associated with the four virus serotypes. All four serotypes can co-circulate within a region, in which a number of regions are hyperendemic for all 4 serotypes. Currently, there are no specific treatment or vaccine for the disease. Dengue prevention depends on vector control measures and early interventions. The COVID-19 pandemic has placed immense pressure on health care and management systems worldwide. During the COVID-19 pandemic, the situation was aggravated by the simultaneous dengue outbreaks, that has led to a double burden which has further impacted the healthcare sector, particularly in resource limited settings. This review article will focus on dengue epidemics during the COVID-19 pandemic and discuss on recent findings on immunological cascades between dengue and COVID-19 and, the impact on vaccine development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 773 | 0 | 8 | |i Enthalten in |t Uirusu |d 1972 |g 71(2021), 1 vom: 06., Seite 1-10 |w (DE-627)NLM000245429 |x 0042-6857 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2021 |g number:1 |g day:06 |g pages:1-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2222/jsv.71.1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2021 |e 1 |b 06 |h 1-10 | ||